Navigation Links
Medimetriks Pharmaceuticals Launches Two New Prescription Brands
Date:4/27/2009

FAIRFIELD, N.J., April 27 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company launched Centany(R) (mupirocin ointment, 2%) and Uramaxin(TM) (20% Urea) Foam to its core Dermatology and Podiatry physician audiences. Centany(R) received a New Drug Approval in December 2002 and is patented through 2018. Centany(R) represents a significant step in Medimetriks' plan to commercialize patent-protected therapies that offer important patient benefits. Uramaxin(TM) Foam represents a valuable addition to the Company's Uramaxin(TM) Family of urea-based brands. Both of these brands come to Medimetriks as the result of a licensing agreement with Perrigo Company (Nasdaq: PRGO) for U.S. marketing rights.

Centany(R), previously marketed by Johnson & Johnson's Ortho Dermatologics professional division, is indicated for the topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150 million. In addition to a 94% clinical efficacy rate(1) and a 98% eradication of staph and strep*, Centany(R) provides an enhanced safety profile over other mupirocin-based therapies. Centany(R) is the only mupirocin ointment indicated for impetigo free of polyethylene glycol(2), an ingredient found in other mupirocin ointments that carry warnings for patients with impaired kidney function. Centany(R)'s unique vehicle also offers the cosmetically elegant texture of a cream with the occlusive properties of an ointment, providing patients with a therapeutic alternative that may enhance patient compliance. Based on the unique properties of its vehicle, Centany(R) is BX-rated by the FDA and designated as non-substitutable.

Uramaxin(TM) Foam is 20% urea in a vehicle containing ammonium lactate. These components make up the vast majority of prescriptions written by Dermatologists and Podiatrists for dry skin conditions. Uramaxin(TM) Foam is an effective, low-potency keratolytic that complements Uramaxin(TM) (45% Urea) Nail Gel and Uramaxin(TM) (45% Urea) Cream, high-potency keratolytics previously launched by the Company. The foam delivery system is a format gaining wide acceptance by both physicians and patients, and Uramaxin(TM) Foam is provided in a large size to add value to patients. Uramaxin(TM) Foam will compete in a skin softening market that approaches one million prescriptions annually.

Medimetriks CEO and Chairman, Bradley Glassman, commented, "We are pleased to add these prescription brands to our portfolio of therapies that provide value to both patients and physicians. Since the introduction of Medimetriks on May 1st of 2008, the Company has now launched six prescription therapies. These brands will be promoted by an expanding field force that we expect to reach more than 30 professional representatives within the next nine months."

*One week after therapy.

(1)Centany(R) Prescribing Information, Fairfield, NJ: Medimetriks Pharmaceuticals, October 2008.

(2)Data on file, Medimetriks Pharmaceuticals.

Centany(R) is contraindicated in individuals with a history of sensitivity reactions to any of its components. The following local adverse reactions have been reported in connection with the use of Centany(R): application site reactions and pruritus, each in 1% of patients; contact dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.

Uramaxin(TM) Foam is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappears after discontinuing the medication.

Please see full prescribing information at www.medimetriks.com

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.


'/>"/>
SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
2. Medimetriks Pharmaceuticals Launches Companys First Prescription Brands
3. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
4. PUR Water Filtration Systems Can Reduce Trace Levels of Pharmaceuticals Found in Some U.S. Tap Water
5. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
6. Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
9. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
10. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
11. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... Phynd Technologies, Inc. ... GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, NJ. ... three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The ... on New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria ... the country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta ... of New Jersey in the class of 1986, where he graduated in the top ... his current location in Livingston since 1989. He has been a member in good ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... information technology solutions to the healthcare industry, The University of Scranton is adding ... an accelerated path to a career in rapidly growing field of healthcare information. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Super Powder, a supplement produced by Prox ... individuals and dedicated athletes, continues to transform the nutritional supplement industry by providing a ... milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... New York , May 31, 2016 ... other biomaterials market is progressing at a CAGR of ... This market was valued at US$0.46 bn in 2013. ... it is expected to reach US$0.88 bn by the ... data is derived from the market,s holistic representation in ...
(Date:5/31/2016)... ZIONA, Israel , May 31, ... medicine company utilizing its proprietary plant-based rhCollagen technology for ... authorization from the Chief Scientist of Israel,s ... of its NIS 12 million development project for 2016. The ... higher than last year,s authorized grant, which totaled NIS ...
(Date:5/30/2016)... , May 30, 2016 ... research report "Healthcare Biometrics Market by Technology ... Voice)), Multifactor, Multimodal), Application (Workforce Management), End ... to 2021", published by MarketsandMarkets, the market ... by 2021 from USD 1,182.6 Million by ...
Breaking Medicine Technology: